The OCTAVE Study
The Octave (ColoAd1-2001) study is a phase I/II non-randomised multicentre, study of enadenotucirev administered intraperitoneally (IP) to patients with platinum-resistant epithelial ovarian cancer.
The main objective of the phase I part of the study is to determine the dose of enadenotucirev to be used for further studies, either alone or in combination with paclitaxel administered weekly intravenously.
The phase II part of the study aims to determine whether intraperitoneal enadenotucirev has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian cancer.
This trial is currently recruiting subjects in the UK and Spain.
For more information about this trial and the participating centres, please follow these links:
Poster Presented at ASCO 2016